Measuring Biologic Resilience in Older Cancer Survivors.

Abstract

Article Tools REVIEW ARTICLES Caring for Older Adults With Cancer Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.21.00245 Journal of Clinical Oncology - published online before print May 27, 2021 PMID: 34043454 Measuring Biologic Resilience in Older Cancer Survivors Mina S. Sedrak , MD, MS1xMina S. SedrakSearch for articles by this author; Nikesha J. Gilmore, PhD2xNikesha J. GilmoreSearch for articles by this author; Judith E. Carroll , PhD3xJudith E. CarrollSearch for articles by this author; Hyman B. Muss , MD4xHyman B. MussSearch for articles by this author; Harvey J. Cohen, MD5xHarvey J. CohenSearch for articles by this author; and William Dale , MD, PhD1xWilliam DaleSearch for articles by this author Show More 1City of Hope National Medical Center, Duarte, CA2University of Rochester Medical Center, Rochester, NY3University of California, Los Angeles, David Geffen School of Medicine, Jonsson Comprehensive Cancer Center, Jane & Terry Semel Institute for Neuroscience & Human Behavior, Department of Psychiatry & Biobehavioral Sciences, Cousins Center for Psychoneuroimmunology, Los Angeles, CA4Department of Medicine and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC5Duke University Medical Center, Durham, NC https://doi.org/10.1200/JCO.21.00245 First Page Full Text PDF Figures and Tables © 2021 by American Society of Clinical OncologyCONTEXTKey ObjectiveTo highlight the emerging concept of resilience in older cancer survivors, present potential biomarkers of aging that may serve as signatures of resilience, and discuss emerging interventions to promote resilience in this population.Knowledge GeneratedClinically similar older adults with cancer demonstrate variable responses to health stressors. This heterogeneity is attributable to differences in physical or cognitive resilience, defined as the ability to resist or recover function after a health stressor, which diminishes with aging. Measuring age-related biologic processes, such as cellular senescence, epigenetic age acceleration, telomere length, and systemic inflammation, may identify older adults at high risk of functional disability or cognitive decline following cancer therapy. Additionally, interventions targeting these biologic pathways may enhance resilience and promote healthy aging.RelevanceFundamental biologic aging processes influencing resilience following cancer treatment may be targeted to prevent, delay, and treat the adverse aging-related effects of cancer and its treatment.SUPPORTSupport in part by National Cancer Institute (NCI) K12CA001727 (M.S.S.), National Institute on Aging (NIA) R03AG064377 (M.S.S.), University of Rochester CTSA Award No. KL2TR001999 (N.J.G.), NIA P30AG028716 (H.J.C.), NIA K24 AG055693 (W.D.), American Cancer Society 128660-RSG-15-187-01-PCSM (J.E.C.), NCI R01 CA237535 (J.E.C.), and the Waisman Innovation Fund (M.S.S.).AUTHOR CONTRIBUTIONSConception and design: Mina S. Sedrak, Nikesha J. Gilmore, Judith E. Carroll, Hyman B. Muss, Harvey J. Cohen, William DaleFinancial support: William DaleAdministrative support: William DaleCollection and assembly of data: Mina S. Sedrak, Nikesha J. Gilmore, Judith E. Carroll, Hyman B. MussData analysis and interpretation: Judith E. Carroll, Hyman B. Muss, Harvey J. CohenManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTMeasuring Biologic Resilience in Older Cancer SurvivorsThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Mina S. SedrakResearch Funding: Novartis, Seattle Genetics, Lilly, PfizerNo other potential conflicts of interest were reported.